Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS.

Saved in:
Bibliographic Details
Title: Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS.
Authors: Zweegman S; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, France., Facon T; Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille, Lille, France., Hungria V; Clinica São Germano, São Paulo, Brazil., Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Venner CP; BC Cancer Agency, Vancouver, British Columbia, Canada., Braunstein M; NYU Grossman Long Island School of Medicine, Mineola, New York, United States., Pour L; University Hospital Brno, Brno, Czech Republic., Marti J; Hospital la Mutua de Terrassa, Terrassa, Spain., Basu S; The Royal Wolverhampton NHS Trust and University, Wolverhampton, United Kingdom., Cohen YC; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Matsumoto M; National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan., Suzuki K; Japanese Red Cross Medical Center, tokyo, Japan., Hulin C; CHU Bordeaux, Hopital haut Leveque, centre François Magendie, PESSAC, France., Legiec WM; St. John of Dukla Oncology Center of Lublin Land and Institute of Medical Science, Faculty of Medicine, The John Paul II Catholic University, Lublin, POLAND, Poland., Beksac M; Istinye University, Ankara, Turkey., Maiolino A; Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Takamatsu H; Kanazawa University, Kanazawa, Japan., Perrot A; Université de Toulouse, CHU Toulouse, Toulouse, France., Turgut M; 19 mayis university, samsun, Turkey., Liu W; Janssen China Research & Development., Wang J; Janssen Pharmaceuticals, Belle Mead, New Jersey, United States., Van Brummelen E; Johnson & Johnson Innovative Medicine, Leiden, Netherlands., Krevvata M; Janssen Research & Development, LLC, Spring House, Pennsylvania, United States., Lopez-Masi L; Janssen Research & Development, LLC, Middletown, New Jersey, United States., Carey J; Janssen Research & Development, LLC, Spring House, Pennsylvania, United States., Borgsten F; Janssen Research & Development, LLC, Raritan, New Jersey, United States., Rowe M; Janssen Research & Development, High Wycombe, United Kingdom., Carson R; Janssen R&D, Springhouse, Pennsylvania, United States., Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Source: Blood advances [Blood Adv] 2026 Jun 03. Date of Electronic Publication: 2026 Jun 03.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2026019937